Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Viridian Therapeutics Inc (NQ: VRDN ) 14.98 +0.51 (+3.52%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 987,561 Open 14.67 Bid (Size) 14.53 (1) Ask (Size) 16.19 (5) Prev. Close 14.47 Today's Range 14.31 - 15.12 52wk Range 10.93 - 24.18 Shares Outstanding 9,587,155 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense July 16, 2024 Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine. Via Investor's Business Daily Expert Ratings For Viridian Therapeutics July 16, 2024 Via Benzinga Performance YTD -32.98% -32.98% 1 Month +13.40% +13.40% 3 Month +4.76% +4.76% 6 Month -25.10% -25.10% 1 Year -25.55% -25.55% More News Read More 3 Small-Cap Stocks With Explosive 2X Growth Potential July 08, 2024 Via InvestorPlace Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 03, 2024 From Viridian Therapeutics, Inc. Via Business Wire 7 Analysts Assess Viridian Therapeutics: What You Need To Know June 06, 2024 Via Benzinga Unveiling 4 Analyst Insights On Viridian Therapeutics March 20, 2024 Via Benzinga Navigating 6 Analyst Ratings For Viridian Therapeutics February 28, 2024 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session June 11, 2024 Via Benzinga Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease June 11, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 06, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences May 31, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics to Participate in Upcoming May Investor Conferences May 10, 2024 From Viridian Therapeutics, Inc. Via Business Wire VRDN Stock Earnings: Viridian Therapeutics Beats EPS, Beats Revenue for Q1 2024 May 08, 2024 Via InvestorPlace Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results May 08, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 03, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024 April 29, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 04, 2024 From Viridian Therapeutics, Inc. Via Business Wire Finding the Next Big Winners: 3 Stocks You Can Snag for Under $20 March 19, 2024 Via InvestorPlace Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 06, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference March 05, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results February 27, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer February 16, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) February 06, 2024 From Viridian Therapeutics, Inc. Via Business Wire Here's Why Viridian Therapeutics (VRDN) Stock Is Moving January 18, 2024 Via Benzinga Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock January 17, 2024 From Viridian Therapeutics, Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.